Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cephalexin Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 8/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | SLC15A2 | Q16348 | 3/20 | 0.98 |
| ▸ | HPGD | P15428 | 3/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.98 |
| ▸ | BLM | P54132 | 2/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | HTR2B | P41595 | 1/20 | 0.98 |
| ▸ | MEN1 | O00255 | 5/20 | 0.83 |
| ▸ | LMNA | P02545 | 2/20 | 0.83 |
| ▸ | ESR1 | P03372 | 1/20 | 0.83 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.83 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.83 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cephalexin Anhydrous SCHEMBL2353794 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL21962879 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL27943595 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL3002253 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL41911 | 1.00 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL582342 | 0.99 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL4928314 | 0.99 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL27742537 | 0.99 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL4928321 | 0.99 | HSD17B10 (0.98) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 | |
| Cephalexin Anhydrous SCHEMBL10713860 | 0.99 | HSD17B10 (1.00) | HSD17B10MAPTALDH1A1KMT2ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3880122-A1 | SYSTEMS AND METHODS OF PREPARING A GRAFT | Genesis Biologics, Inc. (US) | 2021-09-22 | — | — | EP | disclosed |
| US-20210212809-A1 | SYSTEMS AND METHODS OF PREPARING A GRAFT | GENESIS BIOLOGICS, INC. (US) | 2021-07-15 | — | — | US | disclosed |
| WO-2020102438-A1 | SYSTEMS AND METHODS OF PREPARING A GRAFT | GENESIS BIOLOGICS, INC. (US) | 2020-05-22 | — | — | WO | disclosed |
| US-8008345-B2 | Preventing, alleviating symptoms of a skin condition with a complexes, such as lauryliminodipropionic acid tocopheryl phosphate; penetrating and absorption into skin; inflammation, erythema, wound, burn, dermatitis, gingivitis, sunburn, heat burn, psoriasis; cosmetics | VITAL HEALTH SCIENCES PTY. LTD. (AU) | 2011-08-30 | — | — | US | disclosed |
| EP-1420797-A4 | DERMAL THERAPY USING PHOSPHATE DERIVATIVES OF ELECTRON TRANSFER AGENTS | VITAL HEALTH SCIENCES PTY LTD (AU) | 2005-03-02 | — | — | EP | disclosed |
| US-20040253318-A1 | Dermal therapy using phosphate derivatives of electron transfer agents | ISP INVESTMENTS LLC | 2004-12-16 | — | — | US | disclosed |
| EP-1420797-A1 | DERMAL THERAPY USING PHOSPHATE DERIVATIVES OF ELECTRON TRANSFER AGENTS | Vital Health Sciences Pty Ltd. (AU) | 2004-05-26 | — | — | EP | disclosed |
| WO-2003011303-A1 | DERMAL THERAPY USING PHOSPHATE DERIVATIVES OF ELECTRON TRANSFER AGENTS | VITAL HEALTH SCIENCES PTY LTD (AU) | 2003-02-13 | — | — | WO | disclosed |
| EP-0143658-A2 | Improvements in or relating to cephalosporin derivatives | ELI LILLY AND COMPANY (US) | 1985-06-05 | — | — | EP | disclosed |